CTNM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 12:58):

Stats
Today's Volume	11 437.00
Average Volume	161 150
Market Cap	358.99M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.226 (1.58%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-09	Johnson & Johnson	Buy	0	Class A Common Stock

INSIDER POWER
0.00
Last 0 transactions
Buy: 0 \| Sell: 0

Volume Correlation

Long: 0.18 (neutral)

Short: 0.78 (moderate)

Signal:(45.399) Neutral

Contineum Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Contineum Therapeutics, Correlation - Currency/Commodity

0.46
( neutral )

0.44
( neutral )

-0.28
( neutral )

0.20
( neutral )

-0.35
( neutral )

-0.43
( neutral )

Financial Reports:

No articles found.

Contineum Therapeutics,

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.